Results from two studies presented at ESMO 2019 in patients with locally advanced resectable gastric cancer - the PRODIGY and RESOLVE trials - demonstrate the benefit of perioperative chemotherapy regimens as reported by Prof. Ian Chau from The Royal Marsden Hospital NHS Foundation Trust, Sutton, UK. The presented data may have a significant impact on clinical practice, especially in Asian countries.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.